Telacebec: an investigational antibacterial for the treatment of tuberculosis (TB).
Bei Shi LeeKevin PethePublished in: Expert opinion on investigational drugs (2022)
The first phase 2a trial showed a correlation between dosage and bacterial load in patient sputum, which should be confirmed using a direct measurement method such as colony-forming unit counting. Its clinical efficacy, favorable pharmacokinetic properties, low arrhythmogenic risk, and activity against MDR-TB strains make telacebec a suitable candidate for further development. Future clinical testing in combination with approved second-line drugs will reveal its full potential against MDR-TB. Considering recent preclinical studies, we also recommend initiating clinical trials for Buruli ulcer and leprosy.
Keyphrases
- mycobacterium tuberculosis
- clinical trial
- phase ii
- pulmonary tuberculosis
- multidrug resistant
- phase iii
- escherichia coli
- study protocol
- cystic fibrosis
- case report
- open label
- randomized controlled trial
- current status
- gene expression
- cell therapy
- emergency department
- mesenchymal stem cells
- silver nanoparticles
- antiretroviral therapy